Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ABBVIE INC [US]”

30 pharma patents match "ABBVIE INC [US]" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 30
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 30 pharmaceutical patents matching "ABBVIE INC [US]" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

30 results for “ABBVIE INC [US]” · 30,257 patents in full index Clear search

  1. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    ABBVIE INC [US] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  2. EP 4670742

    ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE

    ABBVIE INC [US] · Granted Dec 31, 2025 · Expires Dec 26, 2045

    granted
  3. US 2025333394

    Tiparp Inhibitor Compounds

    ABBVIE INC [US] · Granted Oct 30, 2025 · Expires Oct 25, 2045

    granted
  4. EP 4640274

    LPAR1-INHIBITOREN

    ABBVIE INC [US] · Granted Oct 29, 2025 · Expires Oct 24, 2045

    granted
  5. US 2025325692

    METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES

    ABBVIE INC [US] · Granted Oct 23, 2025 · Expires Oct 18, 2045

    granted
  6. WO 2025221754

    UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES

    ABBVIE INC [US] · Granted Oct 23, 2025 · Expires Oct 18, 2045

    granted
  7. WO 2025198916

    ANTICORPS ANTI-TAU

    ABBVIE INC [US] · Granted Sep 25, 2025 · Expires Sep 20, 2045

    granted
  8. US 2025250277

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] · Granted Aug 7, 2025 · Expires Aug 2, 2045

    granted
  9. US 2025235515

    CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS AND IMPROVED DRYING PROCESSES

    ABBVIE INC [US] · Granted Jul 24, 2025 · Expires Jul 19, 2045

    granted
  10. WO 2025147499

    LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE

    ABBVIE INC [US] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  11. WO 2025137347

    FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION

    ABBVIE INC [US] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  12. EP 4563165

    PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE

    ABBVIE INC [US] · Granted Jun 4, 2025 · Expires May 30, 2045

    granted
  13. WO 2025111258

    COMPOSITIONS DE SÉROTYPE A DE NEUROTOXINE DE CLOSTRIDIUM BOTULINUM ET PROCÉDÉS DE FILTRATION AMÉLIORÉS

    ABBVIE INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted
  14. US 2025057837

    Methods for Treating HCV

    ABBVIE INC [US] · Granted Feb 20, 2025 · Expires Feb 15, 2045

    granted
  15. US 2025059280

    METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

    ABBVIE INC [US] · Granted Feb 20, 2025 · Expires Feb 15, 2045

    granted
  16. US 2025049789

    METHODS OF TREATING ALOPECIA ARAETA

    ABBVIE INC [US] · Granted Feb 13, 2025 · Expires Feb 8, 2045

    granted
  17. US 2025034157

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  18. US 2024398790

    TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB

    ABBVIE INC [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  19. WO 2024249235

    CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN

    ABBVIE INC [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  20. US 2024390367

    METHODS OF TREATING VITILIGO WITH UPADACITINIB

    ABBVIE INC [US] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  21. WO 2024243450

    MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET

    ABBVIE INC [US] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  22. WO 2024211523

    SCHÉMAS POSOLOGIQUES DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION DE LA RECHUTE DE LA LEUCÉMIE MYÉLOÏDE AIGUË APRÈS UNE TRANSPLANTATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ALLOGÉNIQUES AVEC DU VÉNÉTOCLAX EN COMBINAISON AVEC DE L'AZACITIDINE

    ABBVIE INC [US] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  23. WO 2023077094

    TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR

    ABBVIE INC [US] · Granted May 4, 2023 · Expires Apr 29, 2043

    granted
  24. CA 3207179

    METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE

    ABBVIE INC [US] · Granted Jul 14, 2022 · Expires Jul 9, 2042

    granted